Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 3, Issue 5, Pages 527-535Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/EHM.10.53
Keywords
anticoagulant; antithrombin; argatroban; cardiovascular disease; direct thrombin inhibitor; heparin-induced thrombocytopenia; ischemic stroke; percutaneous coronary intervention
Categories
Ask authors/readers for more resources
Argatroban is a synthetic, small-molecule direct thrombin inhibitor that is approved in the USA, the EU and Japan for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT), and for anticoagulation of HIT patients undergoing PCI. Argatroban binds reversibly to, and inhibits both soluble and clot-bound thrombin. Argatroban does not generate antibodies, is not susceptible to degradation by proteases and is cleared hepatically. It has a predictable anticoagulant effect and there is a good correlation between dose, plasma concentration and pharmacodynamic effect. Initial clinical studies suggest that further investigations to establish the use of argatroban in ischemic stroke, acute coronary syndrome, hemodialysis, blood oxygenation, off-pump cardiac surgery and other clinical indications are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available